<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8406">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02137304</url>
  </required_header>
  <id_info>
    <org_study_id>2013-A01771-44</org_study_id>
    <nct_id>NCT02137304</nct_id>
  </id_info>
  <brief_title>A Method to Optimize Mecanical In-exsufflation in Neuromuscular Diseases</brief_title>
  <acronym>COUGHELP</acronym>
  <official_title>A Method to Optimize Mecanical In-exsufflation in Neuromuscular Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre d'Investigation Clinique et Technologique 805</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre d'Investigation Clinique et Technologique 805</source>
  <oversight_info>
    <authority>France : ANSM-French Health Products Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators want  to demonstrate that there is an optimal expiratory pressure when
      using mecanical in-exsufflation for each patient in neuromuscular disease. This compromise
      is between the need to generate a high pressure difference between alveoli and the mouth and
      the need to avoide and superior airways collapsus.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>optimal negative pressure treshold value</measure>
    <time_frame>20 minutes</time_frame>
    <safety_issue>No</safety_issue>
    <description>Optimal negative pressure treshold value measured  for a flow superior or equal to 160 liter/minute and 270 liter/minute</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>optimal pressure treshold based on the best peak flow.</measure>
    <time_frame>10 minutes</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>volume-flow curve aspect</measure>
    <time_frame>5 minutes</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Neuromuscular Disease</condition>
  <arm_group>
    <arm_group_label>neuromuscular patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neuromuscular patients with cough inefficiency requiring a mechanical in-exsufflation support.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cough Assist® (JH Emerson Compagny, Cambridge, MA, USA)</intervention_name>
    <arm_group_label>neuromuscular patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  man or female age18 years

          -  neuromuscular disease

          -  coughassist adaptation treatment

          -  peak cough flow&lt;270liter/minute

        Exclusion Criteria:

          -  acute organ failure

          -  insufflation contrindication

          -  pregnant women/no affiliation to a social security scheme

          -  plan of legal protection
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hôpital R. POINCARE</name>
      <address>
        <city>Garches</city>
        <zip>92380</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 9, 2014</lastchanged_date>
  <firstreceived_date>April 17, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cough help</keyword>
  <keyword>in-exsufflation</keyword>
  <keyword>neuromuscular disease</keyword>
  <keyword>cough assistance optimization</keyword>
  <keyword>efficient cough flow</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neuromuscular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
